Decorative image

Targeted cancer drug treatment

Targeted cancer drugs are treatments that change the way cells work and help the body to control the growth of cancer. They work by ‘targeting’ the differences that help a cancer cell to survive and grow.

Treatments for bowel cancer

Some types of targeted drugs are used to treat colon or rectal cancer that has spread to other parts of the body (advanced or metastatic bowel cancer). They can shrink the cancer or slow its growth but they can't cure the cancer.

These types of treatment help the body to control the growth of cancer cells. 

They can work by:

  • stopping cancer cells from growing and dividing 
  • seeking out and killing cancer cells 
  • encouraging the immune system to kill cancer cells 
  • stopping the blood and nutrient supply to the cancer

Whether you have targeted therapy depends on:

  • the type of cancer you have 
  • how far the cancer has grown (the stage)
  • other treatments you've already had 

Types of targeted drug treatments for bowel cancer

Monoclonal antibodies 

Monoclonal antibodies work by recognising and finding specific proteins on cancer cells. Different types of cancer have different proteins. The monoconal antibody stops particular proteins from binding to cancer cells or blocking it from triggering the cancer cells to divide and grow.

Diagram showing a monoclonal antibody attached to a cancer cell

Monoclonal antibodies for bowel cancer include:

  • cetuximab (Erbitux)
  • panitumumab (Vectibix) 
  • bevacizumab (Avastin)

You might have monoclonal antibodies during or after chemotherapy.

Anti angiogenesis drugs 

Angiogenesis means the growth of new blood vessels. A cancer needs a good blood supply to bring food and oxygen and remove waste products. Some cancer drugs stop the blood supply to cancer cells. These drugs are called anti angiogenics.

Aflibercept (Zaltrap) is an anti angiogenesis drug for advanced bowel cancer.

Cancer growth blockers 

Regorafenib (Stivarga) is a growth blocker. It works by blocking particular proteins on cancer cells that encourage the cancer to grow. It also stops the cancer from growing blood vessels. 

Are these drugs available in the UK?

Cetuximab and panitumumab

Cetuximab and panitumumab are available on the NHS for advanced bowel cancer throughout the UK.

You can have these drugs:

  • if genetic tests on your cancer cells show these drugs might help you
  • as the first treatment for your advanced cancer, in combination with chemotherapy

Bevacizumab​ and regorafenib

These drugs have been licensed to treat advanced bowel cancer. But they have not been approved by the National Institute for Health and Care Excellence (NICE) or the Scottish Medicines Consortium (SMC). So they are not routinely available as treatments on the NHS in the UK.

Aflibercept

Aflibercept has been licensed to treat advanced bowel cancer. But it has not been approved by NICE. So it isn’t routinely available on the NHS in England, Wales or Northern Ireland.

Aflibercept is available in Scotland. The SMC have recommended aflibercept for advanced bowel cancer:

  • together with irinotecan and 5FU chemotherapy (FOLIFIRI)
  • as your second treatment for advanced bowel cancer, if your first treatment (which included oxaliplatin chemotherapy) is no longer working 

General side effects

Side effects depend on the type of drug you are having, some of the common side effects include:

  • tiredness (fatigue)
  • loss of appetite 
  • a sore mouth 
  • low levels of blood cells 
  • feeling sick

Contact your doctor or nurse if you are having any problems. They can give you advice and medication to help with some side effects.

Targeted drugs and their side effects

Last reviewed: 
18 May 2018
  • Metastatic colorectal cancer
    ESMO clinical practice guidelines for diagnosis, treatment and follow up
    E van Cutsem and others
    Annals of Oncology 2014 Vol 25 (suppl 3): iii1-iii9

  • Colorectal cancer: the diagnosis and management of colorectal cancer
    The National Institute of Health and Care Excellence, November 2011

  • Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
    J Duillard and others
    New England Journal of Medicine 2013 Sep 12;369(11):1023-34

  • Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer
    C Vaughn and others
    Genes Chromosomes Cancer. 2011 May;50(5):307-12

  • NRAS mutations are rare in colorectal cancer
    N Irahara and others
    Diagnostic Molecular Pathology 2010 Sep;19(3):157-63

Information and help

Dangoor sponsorship

About Cancer generously supported by Dangoor Education since 2010.